Livdelzi (seladelpar) granted accelerated approval for primary biliary cholangitis by FDA – Gilead Sciences
Gilead Sciences, Inc. announced that the FDA has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA)… read more.